



---

March XX, 2020

Dear SMA Community,

Following your request, we want to provide an update on Biogen's efforts to help ensure the health and safety of the SMA community amid the novel Coronavirus (COVID-19), as well as the steps we are taking to address these challenging times.

We are ensuring continuous supply of our medicines to patients, and at this time, we continue to operate our manufacturing facilities and supply our therapies, for people around the world. As of now, there is no shortage of SPINRAZA and treatment remains available to patients. While we currently do not anticipate any interruptions, rapidly changing efforts to contain the spread of COVID-19 may have an impact in the future on our ability to manufacture or supply our therapies in certain areas of the world.

We are continuing the clinical trials we have underway in sites across the globe. We are monitoring this dynamic situation closely and expect that COVID-19 precautions may impact the timeline of some of our trials, particularly those that are actively enrolling and monitoring patients.

Finally, we are aware that some patients treated with SPINRAZA are temporarily having their dosing postponed as part of health system efforts in their region or country to prioritize potential COVID-19 patients. We are working with health systems, institutions and physicians to help navigate these unprecedented times while also providing access to a critical therapy for people with SMA. The Biogen team is providing relevant scientific support for physicians to make informed patient treatment decisions.

Thank you for your understanding and collaboration. We remain available to answer your questions, and please don't hesitate to contact us.

Best Regards,

The Biogen SMA Team